We have placed cookies on your computer to help make this website better. We use a Matomo Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by Matomo (e.g. deny use/opt-out).

I'm ok with this

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

... About us

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 155 countries and we employ around 5,200 employees worldwide.

... Company Overview

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

Beyond our overarching purpose – to improve the health of people around the globe – we want to create shared value through sustainability for our company and society as a whole.

... Responsibility

In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Patients’ needs are at the heart of everything we do; using our passion for science, we develop long-lasting solutions that directly address these needs.

... Products

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.

... Research & Development

For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient, the use of big data and state-of-the-art technologies such as devices that result in innovative solutions for the patients need.

... Strategy

Our R&D pipeline is a source of great excitement – we currently have several new drug candidates and technologies in different phases of development.

... Pipeline

Our key innovation area is pain.

... Focus area

Collaboration with the scientific community is central to our R&D strategy. Let’s work together – collaborate with us!

... Collaborate with us

We believe that success comes from close collaborations founded on a shared vision to develop innovative medicines for patients that suffer from diseases with high unmet needs.

... Partnering

We strengthen and develop our core markets Europe, North America, Latin America and Asia through acquisitions, asset deals, in-licensing, commercialization and distribution deals.

... Areas of interest

We work with the world’s biggest public-private partnership organisation in the life sciences as co-leaders of the latest pain initiative.

... Public Private Partnerships

Protecting our future

Our actions as humans have had a detrimental impact on the environment; natural resources are in decline and air and water pollution are affecting flora, fauna and our own health.

We know we can’t solve these problems overnight, but we are committed to actively doing our bit. Our Environment, Health & Safety department (EHS) is responsible for ensuring that we use our resources in a sustainable manner to avoid waste where possible. By using our environmental and energy management system in accordance with ISO 14001 and ISO 50001, we ensure that we adhere to all relevant legal regulations.

As a matter of course, we collect, measure and analyse the energy consumption of our production sites and use these data to implement energy efficiency projects.

Certificates

2018-10-10 Z-Grnenthal Pharma-14001-2015-en.pdf 1 MB

2018-10-10 Z-Grnenthal Pharma-18001-en.pdf 1 MB

hours a year¹

8,000

kWh of electricity²

100,000

kWh³

4,380,000

¹ In 2016, we built a combined heat-and-power station in Aachen operating 8,000 hours a year and generating electricity (16 GWh) and heat (16.5 GWh) that is then used in production and heating systems.

² A photovoltaic plant has been in operation on the roof of one of our buildings in Aachen since the end of 2012. It has generated approximately 100,000 kWh of electricity so far.

³ Energy equivalent that is saved by the use of groundwater under our Swiss production site in order to cool down the API production. It is returned to the underground stream without any contamination.

Handling of effluents and waste

The reduction and safe handling of waste water and waste is part of our operations. Each production site has dedicated staff involved in the processes. In particular, the environmental-management system ensures that waste is sorted so that as much as possible is recycled, and disposal routes are in compliance with national legislations.

Grünenthal Sustainability Report 2015 2 MB

Efficiency¹

92 %

Contamination²

0 %

Local waste disposal³

100 %

¹ Efficiency of the recycling process for the solvent tetrahydrofuran THF on our Swiss site in 2015.

² In 2015, no significant spills or contaminations occurred at any of our five production sites.

³ In 2015, at all five production sites, 3,230 tons of hazardous waste was generated. All this waste was treated locally by licensed disposal companies. No waste was exported.